Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Multilingualism and exclusion to be discussed
2007-11-27

 
 Some of the UFS staff who will be attending the colloquium on multilinguisim and exclusion in Antwerp, Belgium are, from the left, front: Prof. Theo du Plessis and Ms Susan Lombaard; back: Prof. Johan Lubbe and Mr Roelof Geyser. All are from the Unit for Language Management.
 
Multilingualism and exclusion to be discussed

Five members of the University of the Free State’s (UFS) Unit for Language Management will be taking part in an international colloquium at the University of Antwerp in Belgium on the theme: “Multilingualism and exclusion – perspectives on language and society” this week.

“During this week’s colloquium, approximately twenty South African and Flemish colleagues will reflect on the complex relationships within multilingual communities, where a variety of factors can contribute to the inclusion or exclusion of individuals or communities. Some of the papers will focus on policy measures (“from above”) with regard to the relative position of languages in a particular state, and the impact of these policy measures on the lives of language users. Others will investigate perceptions and “appropriation” (“from below”) by the same language user. In view of the multiple points of departure, the colloquium should contribute towards a better understanding of the dynamics within multilingual communities,” said Prof. Theo du Plessis, Director of the Unit for Language Management at the UFS.

“To give expression to the theme of multilingualism and exclusion, lectures will be presented in three languages, namely Afrikaans, English and Dutch. Several postgraduate students (from South Africa and Flanders) will also have an opportunity to report on investigations they are conducting within the framework of their master’s degree and doctoral studies,” said Prof. Du Plessis.

The colloquium is a follow-up of an international symposium held at the UFS during April 2006 in which a considerable number of outstanding scholars from various countries participated.

According to Prof. Du Plessis, the proceedings of the symposium held last year will be released in book form as part of the unit’s publication series “Studies in Language Policy in South Africa”, published by Van Schaik Publishers.

This sixth issue in the series entitled: “Multilingualism and Exclusion. Policy, Practice, Prospects” will be released tonight (26 November 2007) by the Permanent Deputy of the Province of Antwerp at a prestigious event during the colloquium. The issue was edited by Prof. Du Plessis, Prof. Pol Cuvelier (University of Antwerp), Dr Michael Meeuwis (University of Ghent) and Ms Lut Teck (Institute for Higher Education and the Arts in Brussels).

The UFS will be represented by Prof. Du Plessis, Prof. Johan Lubbe, Ms Susan Lombaard and Mr Roelof Geyser of the Unit for Language Management, as well as Prof. Jackie Naudé of the Department of Afro-Asiatic Studies, Sign Language and Language Practice. Representatives from the universities of Pretoria, Johannesburg, North West and the Monash University in Johannesburg will also be participating in the colloquium.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za
26 November 2007

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept